SEC Filing Summary: Celsus Therapeutics PLC (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Celsus Therapeutics PLC on March 28, 2014. The filing serves as a report of a material corporate event rather than a periodic financial report. The registrant is a foreign private issuer based in London, United Kingdom.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is not a financial statement and contains no quantitative financial data.
Material Changes
The primary material change disclosed is the resignation of Saul Yedgar from the Board of Directors on March 25, 2014. The resignation was attributed to personal reasons.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the leadership change. The information is incorporated by reference into the Company's Registration Statements on Form F-3 (File Nos. 333-185247, 333-187826, and 333-191880).
Key Facts for Investor Verification
- Saul Yedgar resigned from the Board of Directors on March 25, 2014.
- The resignation was due to personal reasons.
- The filing was signed by Gur Roshwalb, Chief Executive Officer.
- No financial performance data is included in this specific filing.